3,911 reports of this reaction
3.1% of all SODIUM OXYBATE reports
#3 most reported adverse reaction
SOMNOLENCE is the #3 most commonly reported adverse reaction for SODIUM OXYBATE, manufactured by Jazz Pharmaceuticals, Inc.. There are 3,911 FDA adverse event reports linking SODIUM OXYBATE to SOMNOLENCE. This represents approximately 3.1% of all 126,117 adverse event reports for this drug.
SODIUM OXYBATE has an overall safety score of 85 out of 100. Patients taking SODIUM OXYBATE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among SODIUM OXYBATE users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for SODIUM OXYBATE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 3,911 FDA reports for SODIUM OXYBATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 3.1% of all adverse event reports for SODIUM OXYBATE, making it one of the most commonly reported side effect.
If you experience somnolence while taking SODIUM OXYBATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.